TITLE

Association Between Proton Pump Inhibitor Use and Anemia: A Retrospective Cohort Study

AUTHOR(S)
Sarzynski, Erin; Puttarajappa, Chethan; Xie, Yan; Grover, Madhusudan; Laird-Fick, Heather
PUB. DATE
August 2011
SOURCE
Digestive Diseases & Sciences;Aug2011, Vol. 56 Issue 8, p2349
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Proton pump inhibitors (PPIs) are widely prescribed to treat gastrointestinal diseases. However, concerns have been raised regarding their long-term use. Gastric acid suppression may decrease iron absorption, and it remains uncertain whether iron-deficiency anemia may result from chronic PPI therapy. Aims: We aimed to explore the association between chronic PPI use and iron-deficiency anemia. Methods: We conducted a retrospective cohort study of adult patients in an academic outpatient setting who received PPI therapy for at least 1 year between January 1, 2004 and January 1, 2006. We compared the change in hematologic indices among patients receiving PPI therapy for at least 1 year with matched controls. Results: Of the 98 patients on chronic PPI therapy who met inclusion criteria, 35% had no documented indication for such therapy. At baseline, demographics and hematologic indices were similar between PPI-users and controls. Among patients on PPI therapy, all hematologic indices decreased from baseline, including hemoglobin (−0.19 g/dL, P = 0.03), hematocrit (−0.63%, P = 0.02), and mean corpuscular volume (−0.49 fL, P = 0.05). PPI users had significant decreases in mean hemoglobin and hematocrit ( P < 0.01 for both) compared with matched controls. After adjustment for confounders, including rates of esophagogastroduodenoscopy, colonoscopy and remote cancer status, the odds ratio of decreasing hemoglobin by 1.0 g/dL while on chronic PPI therapy was 5.03 (95% CI, 1.71-14.78, P < 0.01), while the odds ratio of decreasing hematocrit by 3% was 5.46 (95% CI, 1.67-17.85, P < 0.01). Conclusions: Among adult patients receiving chronic PPI therapy, there is a significant decrease in hematologic indices from baseline.
ACCESSION #
63286541

 

Related Articles

  • Pantoprazole Therapy in the Long-Term Management of Severe Acid Peptic Disease. Bardhan, Karna Dev; Cherian, Pradip; Bishop, Anne E.; Polak, Julia M.; Perry, Michael J.; Rowland, Anne; Thompson, Mary; Morris, Pamela; Schneider, Andreas; Fischer, Renata; Ng, W.; Lühmann, R.; McCaldin, Brian // American Journal of Gastroenterology;Jun2001, Vol. 96 Issue 6, p1767 

    OBJECTIVE: Pantoprazole is the third proton pump inhibitor to become available. When this study was started, there were few data on its long-term use. Our aim was to investigate this aspect and, because powerful inhibitors of acid secretion can cause hypergastrinemia and, in experimental...

  • Iron-deficiency anaemia, gastric hyperplasia, and elevated gastrin levels due to potassium channel dysfunction in the Jervell and Lange-Nielsen Syndrome. Winbo, Annika; Sandström, Olof; Palmqvist, Richard; Rydberg, Annika // Cardiology in the Young;Jun2013, Vol. 23 Issue 3, p325 

    AimWe investigated extra-cardiac clinical symptoms and signs in the rare Jervell and Lange-Nielsen Syndrome, characterised by impaired KCNQ1 function, a gene essential for gastric acid secretion.MethodsAll Swedish Jervell and Lange-Nielsen cases with double KCNQ1 mutations (14 cases) were...

  • Evolución epidemiológica de la enfermedad ácido péptica en un Centro de endoscopia diagnóstica de Bogotá entre 1993 y 2007. Arango, Luis Alberto Ángel; Boada, Diego Gómez; Díaz, María Paula Villalba // Revista Colombiana de Gastroenterología;Jun2010, Vol. 25 Issue 2, p139 

    Objective: To describe epidemiological characteristics of individuals suffering from acid peptic disease found by a first level endoscopic diagnostic center from 1993 and 2007. Methods: A retrospective, descriptive and analytical study of series of patients. Results: 12,638 registers were...

  • Rabeprazole: quest for the best PPI. Sugano, Kentaro // Journal of Gastroenterology;2002, Vol. 37 Issue 3, p233 

    Editorial. Comments on an article dealing with the effects of proton pump inhibitors (PPI) rabeprazole and omeprazole on parietal cells and other acid regulatory cells in the rat stomach. Details on the study; Background on PPI; Recommendations.

  • Iron Deficiency Anaemia in Young Males: Do Gastrointestinal Symptoms and Haemoglobin Level Affect Diagnostic Yield? Kalla, Rahul; Kwak, Kun; Campbell, Simon; Willert, Robert // Digestive Diseases & Sciences;Oct2013, Vol. 58 Issue 10, p3059 

    No abstract available.

  • Gastric acid suppressants—too much of a good thing? Logan, Ian C.; Sumukadas, Deepa; Witham, Miles D. // Age & Ageing;Jul2010, Vol. 39 Issue 4, p410 

    The author reflects on the adverse effects of the use of gastric acid suppressants, in the form of histamine-2 receptor antagonists (H2RAs) and subsequently proton pump inhibitors (PPIs), particularly to older people. The author emphasizes the adverse effects caused by the use of PPI, including...

  • A review of proton-pump inhibitors. Smith, Haley // South African Pharmaceutical Journal;2014, Vol. 81 Issue 5, p13 

    The introduction of proton-pump inhibitors (PPIs) in the late 1980s optimised the medical treatment of acid-related disorders. PPIs have superseded the use of histamine-2-receptor antagonists in patients with moderate to severe gastric acid-related diseases, as well as for the prophylaxis of...

  • Inhibidores de la bomba de protones y riesgo de infección. Palencia-Herrejón, Eduardo; Artola, Beatriz Sánchez; Rodríguez, Ismael Escobar; Gómez-Lus Centelles, María Luisa // Revista Española de Quimioterapia;Mar2011, Vol. 24 Issue 1, p4 

    Gastric antisecretory drugs, especially proton pump inhibitors, are among the most used drugs both in ambulatory and hospital settings, and prescription does not always follows approved indications. Experimental data suggest that gastric acid inhibition and the effects of proton pump inhibitors...

  • Lansoprazole: In the Management of Gastroesophageal Reflux Disease in Children. Scott, L.J. // Pediatric Drugs;2003, Vol. 5 Issue 1, p57 

    â–´ Lansoprazole, a proton pump inhibitor, inactivates the H/K-ATPase pump in parietal cells, thereby suppressing basal and stimulated gastric acid secretion and increasing intragastric pH. â–´ After 8-12 weeks' treatment with lansoprazole, all children (n = 27) with esophagitis at...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics